Logo image of VYNE

VYNE THERAPEUTICS INC (VYNE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VYNE - US92941V3087 - Common Stock

0.404 USD
+0.03 (+7.22%)
Last: 12/10/2025, 8:23:26 PM
0.4055 USD
+0 (+0.37%)
Pre-Market: 12/11/2025, 6:50:06 AM
Fundamental Rating

3

Overall VYNE gets a fundamental rating of 3 out of 10. We evaluated VYNE against 191 industry peers in the Pharmaceuticals industry. The financial health of VYNE is average, but there are quite some concerns on its profitability. VYNE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VYNE had negative earnings in the past year.
In the past year VYNE has reported a negative cash flow from operations.
In the past 5 years VYNE always reported negative net income.
In the past 5 years VYNE always reported negative operating cash flow.
VYNE Yearly Net Income VS EBIT VS OCF VS FCFVYNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

VYNE has a worse Return On Assets (-93.12%) than 77.49% of its industry peers.
Looking at the Return On Equity, with a value of -104.86%, VYNE is doing worse than 63.87% of the companies in the same industry.
Industry RankSector Rank
ROA -93.12%
ROE -104.86%
ROIC N/A
ROA(3y)-48.52%
ROA(5y)-105.55%
ROE(3y)-60.82%
ROE(5y)-202.97%
ROIC(3y)N/A
ROIC(5y)N/A
VYNE Yearly ROA, ROE, ROICVYNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

VYNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYNE Yearly Profit, Operating, Gross MarginsVYNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

VYNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
VYNE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VYNE has been increased compared to 5 years ago.
There is no outstanding debt for VYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VYNE Yearly Shares OutstandingVYNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
VYNE Yearly Total Debt VS Total AssetsVYNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

VYNE has an Altman-Z score of -29.53. This is a bad value and indicates that VYNE is not financially healthy and even has some risk of bankruptcy.
VYNE has a worse Altman-Z score (-29.53) than 89.53% of its industry peers.
There is no outstanding debt for VYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.53
ROIC/WACCN/A
WACC9.23%
VYNE Yearly LT Debt VS Equity VS FCFVYNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 8.87 indicates that VYNE has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.87, VYNE is doing good in the industry, outperforming 76.96% of the companies in the same industry.
A Quick Ratio of 8.87 indicates that VYNE has no problem at all paying its short term obligations.
VYNE has a better Quick ratio (8.87) than 77.49% of its industry peers.
Industry RankSector Rank
Current Ratio 8.87
Quick Ratio 8.87
VYNE Yearly Current Assets VS Current LiabilitesVYNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

VYNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.30%, which is quite good.
Looking at the last year, VYNE shows a small growth in Revenue. The Revenue has grown by 6.29% in the last year.
VYNE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.63% yearly.
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.38%
Revenue 1Y (TTM)6.29%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%39.67%

3.2 Future

VYNE is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -23.52% yearly.
Based on estimates for the next years, VYNE will show a very strong growth in Revenue. The Revenue will grow by 147.97% on average per year.
EPS Next Y14.28%
EPS Next 2Y0.36%
EPS Next 3Y-21.43%
EPS Next 5Y-23.52%
Revenue Next Year-43.75%
Revenue Next 2Y-18.99%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VYNE Yearly Revenue VS EstimatesVYNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 50M 100M 150M 200M
VYNE Yearly EPS VS EstimatesVYNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VYNE. In the last year negative earnings were reported.
Also next year VYNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYNE Price Earnings VS Forward Price EarningsVYNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYNE Per share dataVYNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as VYNE's earnings are expected to decrease with -21.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.36%
EPS Next 3Y-21.43%

More info and screens

0

5. Dividend

5.1 Amount

VYNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VYNE THERAPEUTICS INC

NASDAQ:VYNE (12/10/2025, 8:23:26 PM)

Premarket: 0.4055 +0 (+0.37%)

0.404

+0.03 (+7.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners14.17%
Inst Owner Change-51.67%
Ins Owners1.29%
Ins Owner Change-2.03%
Market Cap13.45M
Revenue(TTM)524.00K
Net Income(TTM)-33.65M
Analysts78
Price Target3.32 (721.78%)
Short Float %3.81%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.36%
Min EPS beat(2)-28.21%
Max EPS beat(2)42.93%
EPS beat(4)3
Avg EPS beat(4)14.15%
Min EPS beat(4)-28.21%
Max EPS beat(4)42.93%
EPS beat(8)5
Avg EPS beat(8)15.2%
EPS beat(12)6
Avg EPS beat(12)-4.67%
EPS beat(16)10
Avg EPS beat(16)0.78%
Revenue beat(2)1
Avg Revenue beat(2)5.39%
Min Revenue beat(2)-54.9%
Max Revenue beat(2)65.69%
Revenue beat(4)2
Avg Revenue beat(4)66.42%
Min Revenue beat(4)-54.9%
Max Revenue beat(4)296.08%
Revenue beat(8)4
Avg Revenue beat(8)36.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)-38.46%
EPS NY rev (1m)-13.94%
EPS NY rev (3m)-2.93%
Revenue NQ rev (1m)100%
Revenue NQ rev (3m)100%
Revenue NY rev (1m)50%
Revenue NY rev (3m)-35.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.67
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.02
BVpS0.96
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -93.12%
ROE -104.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.52%
ROA(5y)-105.55%
ROE(3y)-60.82%
ROE(5y)-202.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.87
Quick Ratio 8.87
Altman-Z -29.53
F-Score5
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.38%
EPS Next Y14.28%
EPS Next 2Y0.36%
EPS Next 3Y-21.43%
EPS Next 5Y-23.52%
Revenue 1Y (TTM)6.29%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%39.67%
Revenue Next Year-43.75%
Revenue Next 2Y-18.99%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.97%
EBIT growth 1Y-0.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.9%
EBIT Next 3Y-8.76%
EBIT Next 5Y-8.12%
FCF growth 1Y-59.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.37%
OCF growth 3YN/A
OCF growth 5YN/A

VYNE THERAPEUTICS INC / VYNE FAQ

What is the fundamental rating for VYNE stock?

ChartMill assigns a fundamental rating of 3 / 10 to VYNE.


What is the valuation status for VYNE stock?

ChartMill assigns a valuation rating of 0 / 10 to VYNE THERAPEUTICS INC (VYNE). This can be considered as Overvalued.


Can you provide the profitability details for VYNE THERAPEUTICS INC?

VYNE THERAPEUTICS INC (VYNE) has a profitability rating of 0 / 10.


Can you provide the financial health for VYNE stock?

The financial health rating of VYNE THERAPEUTICS INC (VYNE) is 6 / 10.